AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
- Conditions
- Acute Myeloid Leukaemia
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00530699
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 915
- Registration Number
- NCT00528879
- Locations
- 🇺🇸
Clinical Research Advantage / Desert Clinical Res, Llc, Tempe, Arizona, United States
🇺🇸Raikhel, Marina, Torrance, California, United States
🇺🇸Office Of Dr. Gray, Spokane, Washington, United States
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1067
- Registration Number
- NCT00528372
- Locations
- 🇺🇸
Banksville Medical, Pc, Pittsburgh, Pennsylvania, United States
🇺🇸Ritchken & First M.D.'S, San Diego, California, United States
🇺🇸Village Family Practice, Houston, Texas, United States
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT00528411
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2008-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00528905
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)
- Conditions
- DyslipidemiaDiabetes
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT00526552
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1482
- Registration Number
- NCT00526721
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus
- Conditions
- Hypertension
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9000
- Registration Number
- NCT00526279
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )
- Conditions
- DyslipidemiaHypertension
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT00526708
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- Conditions
- HypercholesterolemiaCoronary Heart DiseaseAtherosclerosis
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1743
- Registration Number
- NCT00525824
- Locations
- 🇻🇪
Research Site, Brentwood, Venezuela